{"published_utc": "2025-08-18", "retrieved_date": "2025-08-18", "retrieved_utc": "2025-08-18T11:51:32Z", "source": "NYTimes_World", "title": "Live Updates: Zelensky Heads Back to White House, Facing Hard Choice From Trump", "url": "https://www.nytimes.com/live/2025/08/18/us/trump-zelensky-ukraine-putin", "id_key": "aabc6c4f682543ff32e3e380ccfe01531adc2b2d6fd6927d733298d4f4bbddc9", "summary": "President Volodymyr Zelensky of Ukraine, whose last Oval Office meeting ended in acrimony, was expected to hear a plan from President Trump to cede land to Russia in exchange for security guarantees. European leaders were joining Mr. Zelensky to show support for Ukraine.", "ingested_utc": "2025-08-18T11:51:32Z"}
{"published_utc": "2025-08-18", "retrieved_date": "2025-08-18", "retrieved_utc": "2025-08-18T11:52:17Z", "source": "FinancialPost_Business", "title": "Altius Renews Normal Course Issuer Bid", "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/altius-renews-normal-course-issuer-bid-6", "id_key": "42e74a5173f87440d13e18d22175610817af98228737907c85b0f5589fcb2602", "summary": "ST. JOHN’S, Newfoundland and Labrador — Altius Minerals Corporation (ALS:TSX) (ATUSF: OTCQX) (“Altius” or the “Corporation”) is pleased to announce that it has renewed its Normal Course Issuer Bid (“NCIB”) by which it may purchase at market price up to 1,864,265 common shares (“Shares”), being approximately 4.02% of the 46,315,304 common shares issued and outstanding […]", "ingested_utc": "2025-08-18T11:52:17Z"}
{"published_utc": "2025-08-18", "retrieved_date": "2025-08-18", "retrieved_utc": "2025-08-18T11:52:17Z", "source": "FinancialPost_Business", "title": "Conversion of Senior Unsecured Convertible Debentures Due August 30, 2027", "url": "https://financialpost.com/globe-newswire/conversion-of-senior-unsecured-convertible-debentures-due-august-30-2027", "id_key": "6b0adbdf245a474d33235147fd401b72153085b2305bacdc8b276b39f46b61e2", "summary": "VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company” or “Imperial”) (TSX:III) announces that all outstanding Senior Unsecured Convertible Debentures (the “Debentures”) due August 30, 2027 will be converted into common shares of the Company (“Debenture Shares”), with 100% of the holders of the Debentures (the “Holders”) electing to exercise […]", "ingested_utc": "2025-08-18T11:52:17Z"}
{"published_utc": "2025-08-18", "retrieved_date": "2025-08-18", "retrieved_utc": "2025-08-18T11:52:17Z", "source": "FinancialPost_Business", "title": "180 Degree Capital Corp. and Mount Logan Capital Inc. Announce Revised Terms of Business Combination in Response to Constructive Conversations with Shareholders", "url": "https://financialpost.com/globe-newswire/180-degree-capital-corp-and-mount-logan-capital-inc-announce-revised-terms-of-business-combination-in-response-to-constructive-conversations-with-shareholders", "id_key": "51ce716444a6a960a96f4080191fbb986b1a3288f77bb45b591e9dad5bdfee19", "summary": "180 Degree Capital’s shareholders to receive shares of New Mount Logan based on 110% of Net Asset Value (“NAV”) of 180 Degree Capital at closing, an increase from 100% of NAV New Mount Logan, together with its management, affiliates and related parties, commits to provide an aggregate of US$25 million for shareholder liquidity at or […]", "ingested_utc": "2025-08-18T11:52:17Z"}
{"published_utc": "2025-08-18", "retrieved_date": "2025-08-18", "retrieved_utc": "2025-08-18T11:52:17Z", "source": "FinancialPost_Business", "title": "Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak", "url": "https://financialpost.com/globe-newswire/theratechnologies-announces-filing-of-special-meeting-materials-and-receipt-of-interim-order-in-relation-to-its-acquisition-by-cb-biotechnology-an-affiliate-of-future-pak", "id_key": "a89790b68bfc652c1265a6c7dad2d7a07e518a18fcb9a45babc935dcfca097ec", "summary": "Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement […]", "ingested_utc": "2025-08-18T11:52:17Z"}
{"published_utc": "2025-08-18", "retrieved_date": "2025-08-18", "retrieved_utc": "2025-08-18T11:52:17Z", "source": "FinancialPost_Business", "title": "Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial", "url": "https://financialpost.com/globe-newswire/aptose-reports-early-data-demonstrating-tuspetinib-improves-standard-of-care-treatment-across-diverse-populations-of-newly-diagnosed-aml-in-phase-1-2-tuscany-trial", "id_key": "9d14228a67038fba7b173fe4272821e6c07e8e0508c499ac409ac99bbba306dd", "summary": "Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, […]", "ingested_utc": "2025-08-18T11:52:17Z"}
